Use of Advanced Systemic Therapy in Patients with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry.

Challenge

Real-world data on the characteristics of adult patients with moderate-to-severe AD who had not initiated advanced systemic therapy—despite being clinically eligible—were absent, preventing a precise understanding of the treatment access and prescriber behavior barriers in US routine care.

Solution

The TARGET-DERM AD registry was used to compare demographic characteristics, disease severity, prior treatment exposure, and clinical features between AST-naïve and AST-treated adults with moderate-to-severe AD, with logistic regression identifying independent predictors of remaining AST-naïve.

Impact

Establishing that older age, male sex, and lower disease severity at enrollment independently predict remaining AST-naïve identifies specific patient subgroups most likely to be undertreated, informing prescriber education, trial enrollment design, and access program targeting for AD advanced therapies.